Combination therapy with inhibitors of PRL synthesis (e.g., bromocriptine) and standard HF treatment was found to promote a left ventricular (LV) function recovery and to reduce the risk of cardiovascular outcomes in women with severe PPCM [6, 7], warranting a class IIb, level of evidence B recommendation for bromocriptine by the European Society of Cardiology (ESC) Guidelines on the management of HF during pregnancy [8]. The gene discussed is PRL; the disease is hydrops fetalis.